Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $25.36 and traded as low as $19.27. Amphastar Pharmaceuticals shares last traded at $19.59, with a volume of 534,127 shares.

Analysts Set New Price Targets

Several research analysts have recently commented on AMPH shares. Needham & Company LLC lowered their target price on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company reduced their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Finally, Barclays began coverage on Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $29.50.

Amphastar Pharmaceuticals Price Performance

The business’s 50-day simple moving average is $23.86 and its two-hundred day simple moving average is $25.36. The stock has a market cap of $888.80 million, a price-to-earnings ratio of 9.65, a price-to-earnings-growth ratio of 1.60 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.02 and a quick ratio of 2.90.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24). The firm had revenue of $183.11 million during the quarter, compared to analyst estimates of $190.48 million. Amphastar Pharmaceuticals had a return on equity of 17.58% and a net margin of 13.63%. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 356.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after purchasing an additional 737 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $26,000. Global Retirement Partners LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock worth $27,000 after purchasing an additional 703 shares in the last quarter. Quarry LP acquired a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at $32,000. Finally, GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.